Kintor Pharmaceutical Ltd (HK:9939)
:9939
Want to see HK:9939 full AI Analyst Report?
Top Page
Kintor Pharmaceutical Ltd
(9939)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$2.50
▲(30.21% Upside)
Action:DowngradedDate:01/27/26
The score is held down primarily by weak financial performance (minimal revenue, ongoing losses, and negative free cash flow despite improving burn) and a valuation profile consistent with a loss-making company (negative P/E, no dividend data). Technicals are a support due to a strong uptrend and positive MACD, but extremely overbought RSI/Stoch signals add near-term risk.
Positive Factors
Narrowing net loss and reduced cash burn
A materially smaller net loss and reduced cash burn in 2024 improve the company's runway and lower near-term financing pressure. If sustained, this trend increases the chance management funds key clinical programs to value inflection points without immediate dilution, strengthening execution optionality.
Negative Factors
Minimal revenue and persistent operating losses
Very low revenue versus sustained operating losses signals the business is far from commercial scale. This structural gap implies continued dependence on financing to support R&D and operations, raising the probability that future growth will be delayed absent successful clinical readouts or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Narrowing net loss and reduced cash burn
A materially smaller net loss and reduced cash burn in 2024 improve the company's runway and lower near-term financing pressure. If sustained, this trend increases the chance management funds key clinical programs to value inflection points without immediate dilution, strengthening execution optionality.
Read all positive factors
Kintor Pharmaceutical Ltd (9939) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.44B
Dividend YieldN/A
Average Volume (3M)4.99M
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue Growth557.36%
EPS Growth-24.06%
CountryHK
Employees168
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.28
Shares Outstanding498,660,100
10 Day Avg. Volume2,605,850
30 Day Avg. Volume4,990,601
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.33
Price to Sales (P/S)78.48
P/FCF Ratio-1.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kintor Pharmaceutical Ltd Business Overview & Revenue Model
Company Description
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the P...
How the Company Makes Money
Kintor Pharmaceutical Ltd generates revenue through the development and commercialization of its drug candidates. The company invests in research and development to bring its innovative therapies to market, aiming to secure approvals from regulato...
Kintor Pharmaceutical Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.85M | 5.00M | 0.00 | 0.00 | 34.23M | 0.00 |
| Gross Profit | -28.58M | -4.73M | -67.63M | -21.38M | 34.23M | -7.31M |
| EBITDA | -148.53M | -128.37M | -1.06B | -956.45M | -829.09M | -396.33M |
| Net Income | -180.35M | -155.29M | -1.06B | -954.37M | -842.10M | -508.30M |
Balance Sheet | ||||||
| Total Assets | 391.89M | 515.13M | 869.23M | 2.06B | 2.07B | 1.85B |
| Cash, Cash Equivalents and Short-Term Investments | 52.86M | 147.42M | 455.50M | 875.08M | 1.06B | 1.39B |
| Total Debt | 87.40M | 133.01M | 253.92M | 286.39M | 159.73M | 221.70M |
| Total Liabilities | 175.89M | 221.05M | 411.12M | 559.95M | 412.83M | 343.54M |
| Stockholders Equity | 216.00M | 294.08M | 458.11M | 1.50B | 1.66B | 1.51B |
Cash Flow | ||||||
| Free Cash Flow | -171.71M | -200.76M | -390.30M | -988.73K | -1.13M | -449.92K |
| Operating Cash Flow | -169.59M | -199.08M | -387.58M | -961.26K | -1.05M | -380.88K |
| Investing Cash Flow | 37.16M | 20.03M | 3.27M | 67.19K | 92.00K | -439.73K |
| Financing Cash Flow | -156.72M | -119.67M | -33.46M | 815.75K | 857.42K | 1.78M |
Kintor Pharmaceutical Ltd Technical Analysis
Negative
1.92
Price Trends
2.94
Negative
2.56
Positive
2.37
Positive
Market Momentum
-0.08
Positive
45.60
Neutral
54.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9939, the sentiment is Negative. The current price of 1.92 is below the 20-day moving average (MA) of 2.87, below the 50-day MA of 2.94, and below the 200-day MA of 2.37, indicating a neutral trend. The MACD of -0.08 indicates Positive momentum. The RSI at 45.60 is Neutral, neither overbought nor oversold. The STOCH value of 54.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9939.
Kintor Pharmaceutical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | HK$9.58B | 15.02 | 4.50% | 4.28% | -7.59% | -41.42% | |
60 Neutral | HK$3.49B | -16.66 | -14.53% | ― | -32.12% | -393.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$3.86B | -13.26 | 11.40% | ― | -90.96% | 77.66% | |
48 Neutral | HK$1.44B | -4.06 | -102.50% | ― | 557.36% | -24.06% | |
44 Neutral | HK$776.83M | -6.45 | 191.92% | ― | -100.00% | 77.06% | |
41 Neutral | HK$999.54M | -1.73 | -75.15% | ― | 79.76% | 7.68% |
* Healthcare Sector Average
HK:9939
Kintor Pharmaceutical Ltd
2.87
1.66
137.19%
HK:1875
TOT BIOPHARM International Co. Ltd.
4.58
2.59
130.15%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.38
0.85
55.56%
HK:2197
Clover Biopharmaceuticals Ltd.
2.86
2.65
1261.90%
HK:2257
Sirnaomics Ltd.
6.63
3.59
118.09%
HK:6826
Shanghai Haohai Biological Technology Co., Ltd. Class H
22.26
-1.20
-5.12%
Kintor Pharmaceutical Ltd Corporate Events
Kintor CEO Boosts Stake as Company Doubles Down on Dermatology and Cosmetic Expansion
Jan 26, 2026
Kintor Pharmaceutical Limited announced that its chairman, executive director and CEO, Dr. Youzhi Tong, has increased his stake in the company by purchasing 4.7 million shares on the open market for approximately HK$10.82 million, representing abo...
Kintor Pharmaceutical Sets March Board Meeting to Approve 2025 Annual Results
Jan 26, 2026
Kintor Pharmaceutical Limited has scheduled a board meeting for 26 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025, and to approve their release to the public. T...
Kintor Strikes Exclusive Deal to Market Anti-Hair Loss Foam in Mainland China
Jan 21, 2026
Kintor Pharmaceutical has signed an exclusive sales agency agreement under which its wholly owned subsidiary Koshine Hong Kong will partner with Beijing Dekai Pharmaceutical Technology to market and promote Kintor’s anti-hair loss foam produ...
Kintor Pharmaceutical Announces Board Composition and Roles
Dec 11, 2025
Kintor Pharmaceutical Limited has announced the composition of its board of directors and their respective roles within the company’s committees. This update reflects the company’s governance structure and may influence its strategic d...
Kintor Pharmaceutical Announces Board Changes
Dec 11, 2025
Kintor Pharmaceutical Limited announced the resignation of Mr. Gao as a non-executive director due to his personal and business commitments, effective December 11, 2025. Simultaneously, Mr. Yunfei Chen has been appointed as a non-executive directo...
Kintor Pharmaceutical Completes Share Subscription to Fund Clinical Trials
Nov 21, 2025
Kintor Pharmaceutical Ltd has successfully completed the subscription of new shares, issuing 30,487,500 shares at HK$1.64 each, which represents approximately 6.11% of the company’s enlarged share capital. The net proceeds of approximately H...
Kintor Pharmaceutical to Raise HK$49.78 Million Through Share Subscription
Nov 12, 2025
Kintor Pharmaceutical Ltd has entered into an agreement to issue 30,487,500 new shares to a subscriber wholly owned by China-Singapore Suzhou Industrial Park Ventures Co., Ltd. The shares are priced at HK$1.64 each, representing a discount to rece...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.